Despite the Regulatory Freeze Pending Review, a lot has happened in the first quarter of 2025. To help our clients stay current, we’ve compiled the latest news and developments we think should be on everyone’s radar. EPA Gets More Time to Consider PFAS Primary Drinking Water Rules As reported in WaterWorld, the U.S. EPA has asked for […]
Pace® PFAS News and Views – April 2025 Read More »
USP <797> is often talked about as though compliance is a “pass/fail” test. Either CFU counts are exceeded or they are not. However, the USP <797> mentions data trending several times throughout the standard. In this post, we will look at what data trending is, how it’s used to promote patient safety, and how and
The Importance of Trending in USP <797> Compliance Read More »
According to the EPA, roughly 10% of drinking water systems across the country are discovering elevated levels of PFAS in their drinking water. In a recent webinar, I collaborated with Bryan Pate, CEO of LW Utilities, to discuss some of the latest advancements in PFAS treatment technologies for drinking water. I’ll provide highlights in this
PFAS Treatment Technologies for Drinking Water Read More »
Per- and polyfluoroalkyl substances are called “the forever chemicals” for a reason. These man-made compounds can be incredibly environmentally persistent and have been shown to build up in the tissues of plants, animals, and people. Most widely available PFAS treatment solutions focus on removing the PFAS. However, to solve the challenge of PFAS environmental contamination
PFAS Treatability Studies Read More »
In Q1 of 2025, several states proposed PFAS limits in drinking water to preempt any attempts by the current administration to roll back the current Maximum Contaminant Levels (MCLs) finalized by the U.S. EPA in 2024. In this post, I’ll summarize what we’re seeing and provide insights into what this may mean for our drinking
State Drill Down – PFAS in Drinking Water Read More »
At its essence, USP <797> is a quality control (QC) standard used to protect patients from contamination that can occur when pharmacies produce compounded sterile preparations (CSPs). Media-fill, gloved fingertip, surface sampling, and other tests are used to confirm personnel competency and ensure bioburden control of compounding areas and personnel. For these results to be valid,
USP <797> FAQs: Positive and Negative Controls Read More »